Skip to main content

First patient treated with FATE-NK100

Fate Therapeutics Inc. (Nasdaq: FATE) announced that the first patient has been treated in the DIMENSION study of FATE-NK100 to treat advanced solid tumors. Shares of the biopharmaceutical climbed $1.43 to close at $10.60.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.